AbbVie to present phase 3 etentamig data at myeloma meeting
AbbVie will present promising phase 3 data on a promising new multiple myeloma treatment at an international conference in Scotland. The company's press release reveals that they will share full results from the CERVINO study, which tested etentamig, a cutting-edge bispecific T-cell engager. Early findings show etentamig significantly outperformed existing treatments, meeting key goals for response rate and survival in patients with a specific type of relapsed multiple myeloma.
In addition to etentamig, AbbVie will showcase other experimental drugs like ABBV-2001, a trispecific T-cell engager, and surzetoclax, a BCL-2 inhibitor. They plan to discuss etentamig's performance in various settings, as well as how it works in patients who have tried BCMA-targeting therapies before. The company also intends to explore combination strategies with other treatments.
Etentamig, ABBV-2001, and surzetoclax are experimental medicines awaiting approval. Their safety and effectiveness are being closely monitored in current trials.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
